Orexigen Therapeutics — Investor Presentation (September 2012)
31 slides from Orexigen Therapeutics's investor presentation, Sep 5, 2012
Slide 1: September 2012
Exhibit 99.1 September 2012
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed,“ “probability” an
Slide 3: Path to Commercial Success: Contrave Poised to Deliver
Path to Commercial Success Orexigen: Contrave ® Poised to Deliver Path to approval Large, growing market Unmet need, limited competition Differentiated product profile Skilled partner with heavy resourcing Path to Commercial Success Orexigen: Contrave ® Poised to Deliver Regulatory clarity on the Li
Slide 4: Path to Approval
Path to Approval Path to Approval
Slide 5: The Light Study was designed to satisfy the single approval deficiency identified in the CRL
The Light Study was designed to satisfy the single approval deficiency identified in the CRL CRL identified a single approval deficiency of theoretical CV risk Complete NDA already reviewed by FDA – Efficacy threshold has been met – General safety & tolerability profile established – Positive Ad-Com
Slide 6: The Light Study began enrolling patients June 2012
The Light Study began enrolling patients June 2012 Protocol based on guidance from OND and conducted under a SPA Contrave could be approved with a positive interim analysis at 87 MACE events – Must exclude a doubling of MACE at the interim analysis to be approved – Must exclude a 40% increase at the
Slide 7: Light Study Design
Light Study Design Primary endpoint is ITT analysis of MACE (MI, stroke, CV death) Targeting MACE event rate of 1.5% per year Streamlined study - large sample size, but limited information per subject Contrave32 + WeightMate Placebo + WeightMate Wk 208 Wk 182 Wk 130 Wk 104 Wk 78 Wk 52 Wk 26 Wk 16 Wk
Slide 8: Probability of Technical Success of the Light Study is High
Probability of Technical Success of the Light Study is High Hurdle for approval requires excluding a doubling of CV risk in non- inferiority design, not demonstrating CV benefit Bupropion well characterized in >50M patients over >25 years – Large patient registries and AERS have not identified evide
Slide 9: Our Focus is on Responders to Contrave Therapy
Our Focus is on Responders to Contrave Therapy Illustrative : Typical distribution of weight loss response to obesity therapy Our Focus: Responders Non-responders discontinue drug therapy -10 -20 -30 -40
Slide 10: Responders Maintained Meaningful Weight Loss
Responders Maintained Meaningful Weight Loss Contrave Responders Achieved Significant Weight Loss Represents one year data for responders (patients with 5% weight loss at week per recommended treatment protocol) In the Contrave ® clinical development program the most frequent treatment-emergent adve
Slide 11: Contrave Responders Achieve Improvements Across Multiple Cardiometabolic Parameters
Contrave Responders Achieve Improvements Across Multiple Cardiometabolic Parameters Responders Maintained Meaningful Weight Loss Contrave32 Standardized Mean Change from Baseline at 1 Year Change from Baseline at 1 Year Contrave Responder N=1038 Proportion w/ 5% Wt Loss Wk 16 Contrave Responders Ach
Slide 12: Risk Engine Modeling Suggests Long-term CVD Risk Reduction on Contrave
Risk Engine Modeling Suggests Long-term CVD Risk Reduction on Contrave Risk Engine Modeling Suggests Long-term CVD Risk Reduction on Contrave
Slide 13: Patient demographic targets are based on epidemiologic modeling and clinical trial experience
Patient demographic targets are based on epidemiologic modeling and clinical trial experience Target Current (August) Patient demographic targets are based on epidemiologic modeling and clinical trial experience Age Younger Age Group <25% 14% Gender 50:50 (M:F) 44:56 Minority 15% >20% CV disease 30%
Slide 14: Precise timing of the 87th event dependent on the actual observed event rate
Precise timing of the 87 th event dependent on the actual observed event rate Precise timing of the 87 th event dependent on the actual observed event rate th event 3Q 12 4Q 12 1Q 13 2Q 13 3Q 13 4Q 13 1Q 14 2Q 14 Timing of 87 th event based on 1.5% event rate 2% 1.25% Interim analysis triggered by o
Slide 15: Path to Commercial Success
Path to Commercial Success Path to Commercial Success
Slide 16: Contrave Poised for Commercial Success
Contrave Poised for Commercial Success Market Size / Market Growth Unmet Need / Limited Competition Differentiated Product Profile Heavy Resourcing Contrave Poised for Commercial Success Blockbuster Building Blocks Blockbuster Building Blocks
Slide 17: Obesity: A Large Untapped Market in Need of Solutions
Obesity: A Large Untapped Market in Need of Solutions ~ 1 in 3 People in the US are Obese The obesity epidemic is also expected to grow globally n= ~ 685M people n= ~ 484M people Blockbuster Market Size Blockbuster Market Growth Obesity: A Large Untapped Market in Need of Solutions US Population Sou
Slide 18: Significant Unmet Need in the Market
Significant Unmet Need in the Market Treatment Options Needed Significant Unmet Need in the Market T2DM, 61% of which is attributable to obesity, is an epidemic 1 in 3 adults in the U.S. may have diabetes by 2050 (CDC) Associated with premature death & physical/psychosocial consequences Weight loss
Slide 19: Contrave is Uniquely Positioned for Significant Segments of the Obese Population
Contrave is Uniquely Positioned for Significant Segments of the Obese Population Has diabetes and/or dyslipidemia 62 % Has difficulty controlling eating in response to food cravings 50 % Is depressed or has depressive symptoms 63 % Is female, many of child bearing age 72 % Contrave is Uniquely Posit
Slide 20: Patients With Diabetes On Contrave Achieve Improvements In Glycemic Control with Weight Loss
Patients With Diabetes On Contrave Achieve Improvements In Glycemic Control with Weight Loss Patients With Diabetes On Contrave Achieve Improvements In Glycemic Control with Weight Loss As little as 5 - 10% weight loss has been shown to reduce mortality risk by ~25% Half the Contrave patients who co
Slide 21: Patients with Dyslipidemia Experienced Clinically Significant Improvement in Lipid Profiles
Patients with Dyslipidemia Experienced Clinically Significant Improvement in Lipid Profiles N=87 N=135 N=121 N=184 HDL Cholesterol Triglycerides Patients with Dyslipidemia Experienced Clinically Significant Improvement in Lipid Profiles Placebo P < 0.05 P < 0.05 P < 0.05 P < 0.05 Data is for complet
Slide 22: GEN
& GEN 1-402 11-409
Slide 23: Patients Experienced Statistically Significant Improvements in Eating Control
Patients Experienced Statistically Significant Improvements in Eating Control Patients Experienced Statistically Significant Improvements in Eating Control -20 -15 -10 -5 * * * Change from baseline (mm) -20 -15 -10 -5 * * * Change from baseline (mm) Less More Placebo (N=511) Contrave32 (N=471) How d
Slide 24: Depressed Patients Experienced Significant Weight Loss and Improvements in Depressive Symptoms
Depressed Patients Experienced Significant Weight Loss and Improvements in Depressive Symptoms Depressed Patients Experienced Significant Weight Loss and Improvements in Depressive Symptoms In a 24-week Phase 2 open-label trial of obese depressed patients, Contrave significantly improved measures of
Slide 25: Contrave May Be The Logical Treatment Choice for Women
Contrave May Be The Logical Treatment Choice for Women Contrave May Be The Logical Treatment Choice for Women Source: Orexigen market research; IMS Health, National Disease and Therapeutic Index, Obesity (2010) 18: 347-353 Women seek obesity therapy more than men Women tend to crave food more than m
Slide 26: Empatic is Following Behind Contrave Providing a Different Tool for the Treatment of Obesity
Empatic™ is Following Behind Contrave Providing a Different Tool for the Treatment of Obesity Empatic™ is Following Behind Contrave Providing a Different Tool for the Treatment of Obesity Empatic™ (zonisamide SR / bupropion SR) works by stimulating POMC and inhibiting AGRP/NPY – Enhances 5HT and DA
Slide 27: Empatic Demonstrates Early and Progressive Weight Loss
Empatic Demonstrates Early and Progressive Weight Loss Empatic Demonstrates Early and Progressive Weight Loss The most frequently reported adverse events in patients treated with Empatic were headache, insomnia, nausea and constipation. The most common reasons for discontinuation from treatment were
Slide 28: In a Phase IIa Empatic clinical trial, completers demonstrated 15% weight loss at one year
In a Phase IIa Empatic clinical trial, completers demonstrated 15% weight loss at one year In a Phase IIa Empatic clinical trial, completers demonstrated 15% weight loss at one year Completers Modified ITT-LOCF Week LS mean ± SE ZB-201 through Week 48 Placebo (N=72 through Week 24) ZB360 (N=66 throu
Slide 29: Commercialization plans
Commercialization plans Commercialization plans North American Contrave rights $50mm upfront to Orexigen $1 billion milestones including $100mm before first sale Tiered royalties on net sales from 20 – 35% Takeda has multi-year contractual promotional requirements Orexigen retains a right to co- pro
Slide 30: Attractive Value Proposition for Orexigen
Attractive Value Proposition for Orexigen Attractive Value Proposition for Orexigen Significant revenue potential projected from lead product, Contrave Retained ROW rights for future catalysts and upside Sufficient cash (~$126.2m as of June 30, 2012) to fund operations through Contrave NDA resubmiss
Slide 31: Orexigen
ts OREXIGEN
Orexigen Therapeutics — Investor Presentation (September 2012) on 6ix